Literature DB >> 24862332

Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection.

Eleonora Tavazzi, David Morrison, Peter Sullivan, Susan Morgello, Tracy Fischer1.   

Abstract

HIV-associated neurocognitive disorders (HAND) describes different levels of neurocognitive impairment, which are a common complication of HIV infection. The most severe of these, HIV-associated dementia (HIV-D), has decreased in incidence since the introduction of combination antiretroviral therapy (cART), while an increase in the less severe, minor neurocognitive disorder (MND), is now seen. The neuropathogenesis of HAND is not completely understood, however macrophages (MΦ)s/microglia are believed to play a prominent role in the development of the more severe HIV-D. Here, we report evidence of neuroinflammation in autopsy tissues from patients with HIV infection and varying degrees of neurocognitive impairment but without HIV encephalitis (HIVE). MΦ/microglial and astrocyte activation is less intense but similar to that seen in HIVE, one of the neuropathologies underlying HIV-D. MΦs and microglia appear to be activated, as determined by CD163, CD16, and HLA-DR expression, many having a rounded or ramified morphology with thickened processes, classically associated with activation. Astrocytes also show considerable morphological alterations consistent with an activated state and have increased expression of GFAP and vimentin, as compared to seronegative controls. Interestingly, in some areas, astrocyte activation appears to be limited to perivascular locations, suggesting events at the blood-brain barrier may influence astrocyte activity. In contrast to HIVE, productive HIV infection was not detectable by tyramide signal-amplified immunohistochemistry or in situ hybridization in the CNS of HIV infected persons without encephalitis. These findings suggest significant CNS inflammation, even in the absence of detectable virus production, is a common mechanism between the lesser and more severe HIV-associated neurodegenerative disease processes and supports the notion that MND and HIV-D are a continuum of the same disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24862332      PMCID: PMC4152918          DOI: 10.2174/1570162x12666140526114956

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  22 in total

1.  Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration.

Authors:  Ulrika Wilhelmsson; Lizhen Li; Marcela Pekna; Claes-Henric Berthold; Sofia Blom; Camilla Eliasson; Oliver Renner; Eric Bushong; Mark Ellisman; Todd E Morgan; Milos Pekny
Journal:  J Neurosci       Date:  2004-05-26       Impact factor: 6.167

2.  Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy.

Authors:  Tracy Fischer-Smith; Sidney Croul; Aderonke Adeniyi; Katarzyna Rybicka; Susan Morgello; Kamel Khalili; Jay Rappaport
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

Review 3.  Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.

Authors: 
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

4.  CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation.

Authors:  Babs O Fabriek; Elise S Van Haastert; Ian Galea; Machteld M J Polfliet; Ed D Döpp; Michel M Van Den Heuvel; Timo K Van Den Berg; Corline J A De Groot; Paul Van Der Valk; Christine D Dijkstra
Journal:  Glia       Date:  2005-09       Impact factor: 7.452

5.  Influence of HAART on HIV-related CNS disease and neuroinflammation.

Authors:  I C Anthony; S N Ramage; F W Carnie; P Simmonds; J E Bell
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

6.  Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

7.  The involvement of the cerebral cortex in human immunodeficiency virus encephalopathy: a morphological and immunohistochemical study.

Authors:  A Ciardi; E Sinclair; F Scaravilli; N J Harcourt-Webster; S Lucas
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

8.  TNF-alpha induced over-expression of GFAP is associated with MAPKs.

Authors:  L Zhang; W Zhao; B Li; D L Alkon; J L Barker; Y H Chang; M Wu; D R Rubinow
Journal:  Neuroreport       Date:  2000-02-07       Impact factor: 1.837

9.  Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV.

Authors:  Steven Paul Woods; Julie D Rippeth; Alan B Frol; Joel K Levy; Elizabeth Ryan; Vicki M Soukup; Charles H Hinkin; Deborah Lazzaretto; Mariana Cherner; Thomas D Marcotte; Benjamin B Gelman; Susan Morgello; Elyse J Singer; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-09       Impact factor: 2.475

10.  IL-1β induces GFAP expression in vitro and in vivo and protects neurons from traumatic injury-associated apoptosis in rat brain striatum via NFκB/Ca²⁺-calmodulin/ERK mitogen-activated protein kinase signaling pathway.

Authors:  C Sticozzi; G Belmonte; A Meini; P Carbotti; G Grasso; M Palmi
Journal:  Neuroscience       Date:  2013-08-06       Impact factor: 3.590

View more
  74 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system.

Authors:  Michael D Rizzo; Robert B Crawford; Anthony Bach; Sera Sermet; Andrea Amalfitano; Norbert E Kaminski
Journal:  J Neuroimmunol       Date:  2019-05-20       Impact factor: 3.478

3.  Mitochondrial biogenesis is altered in HIV+ brains exposed to ART: Implications for therapeutic targeting of astroglia.

Authors:  Mary K Swinton; Aliyah Carson; Francesca Telese; Ana B Sanchez; Benchawanna Soontornniyomkij; Leila Rad; Isabella Batki; Brandi Quintanilla; Josué Pérez-Santiago; Cristian L Achim; Scott Letendre; Ronald J Ellis; Igor Grant; Anne N Murphy; Jerel Adam Fields
Journal:  Neurobiol Dis       Date:  2019-06-22       Impact factor: 5.996

4.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

Review 5.  Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.

Authors:  Jay Rappaport; David J Volsky
Journal:  J Neurovirol       Date:  2015-05-02       Impact factor: 2.643

6.  HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate.

Authors:  Dorota Piekna-Przybylska; Kavyasri Nagumotu; Danielle M Reid; Sanjay B Maggirwar
Journal:  J Neurovirol       Date:  2018-11-06       Impact factor: 2.643

7.  Extrapyramidal motor signs in older adults with HIV disease: frequency, 1-year course, and associations with activities of daily living and quality of life.

Authors:  Savanna M Tierney; Steven Paul Woods; David Sheppard; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-12-10       Impact factor: 2.643

8.  Rosiglitazone suppresses HIV-1 Tat-induced vascular inflammation via Akt signaling.

Authors:  Wen Huang; Xuean Mo; Xianghong Wu; Wenjing Luo; Yanlan Chen
Journal:  Mol Cell Biochem       Date:  2015-06-06       Impact factor: 3.396

9.  Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent.

Authors:  Ashok Chauhan
Journal:  Microbes Infect       Date:  2015-06-02       Impact factor: 2.700

10.  Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.

Authors:  Jerel Adam Fields; Brian Spencer; Mary Swinton; Emma Martine Qvale; María J Marquine; Arina Alexeeva; Sarah Gough; Benchawanna Soontornniyomkij; Elvira Valera; Eliezer Masliah; Cristian L Achim; Paula Desplats
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.